37586-22-4

Basic information

• Product Name: 4-BENZOYLPIPERIDINE HYDROCHLORIDE
• Synonyms: 4-BENZOYL PIPERIDINE HCL;TIMTEC-BB SBB003319;PHENYL-PIPERIDIN-4-YL-METHANONE HYDROCHLORIDE;PHENYL(4-PIPERIDINYL)METHANONE;PHENYL(4-PIPERIDYL)METHANONE HYDROCHLORIDE;4-BENZOYLPIPERIDINE;phenyl(4-piperidyl)methanone;Methanone, phenyl-4-piperidinyl-
• CAS NO: 37586-22-4
• Molecular Formula: C₁₂H₁₅NO
• Molecular Weight: 225.71
• Product Categories: Neurochemicals
• Mol File: 37586-22-4.mol
• Article Data: 8

Chemical Properties

• Melting Point: 226 °C
• Boiling Point: 221-224°C
• Flash Point: 125.3 °C
• Appearance: White solid
• Density: 1.054 g/cm³
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4-BENZOYLPIPERIDINE HYDROCHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BENZOYLPIPERIDINE HYDROCHLORIDE(37586-22-4)
• EPA Substance Registry System: 4-BENZOYLPIPERIDINE HYDROCHLORIDE(37586-22-4)

Safety Data

• Hazard Codes: T
• Statements: 25
• Safety Statements: 45
• HazardClass: IRRITANT
• Hazardous Substances Data: 37586-22-4(Hazardous Substances Data)

Usage

Chemical Properties

White Solid

InChI:InChI=1S/C12H15NO/c14-12(10-4-2-1-3-5-10)11-6-8-13-9-7-11/h1-5,11,13H,6-9H2

Upstream product

• 25519-79-3 1-(4-benzoylpiperidin-1-yl)ethanone 
• 109555-51-3 1-benzoyl-4-benzoylpiperidine 
• 190142-48-4 4-piperidinylcarbonyl chloride 
• 71-43-2 benzene 
• 31252-42-3 4-benzylpyperidine 

Downstream Products

• 117022-85-2 1-{4-[3-(4-benzoyl-piperidin-1-yl)-propoxy]-3-methoxy-phenyl}-ethanone 
• 141620-44-2 (1-Oxiranylmethyl-piperidin-4-yl)-phenyl-methanone 
• 112946-49-3 1-(2-{2-[4-(4-Benzoyl-piperidin-1-yl)-butoxy]-5-chloro-phenyl}-benzothiazol-3-yl)-ethanone 
• 112946-67-5 1-(2-{2-[3-(4-Benzoyl-piperidin-1-yl)-propoxy]-5-methoxy-phenyl}-benzothiazol-3-yl)-ethanone 
• 86136-36-9 1-(2-{2-[4-(4-Benzoyl-piperidin-1-yl)-butoxy]-5-methoxy-phenyl}-benzothiazol-3-yl)-ethanone 
• 112946-69-7 1-(2-{2-[5-(4-Benzoyl-piperidin-1-yl)-pentyloxy]-5-methoxy-phenyl}-benzothiazol-3-yl)-ethanone 
• 112946-63-1 1-(2-{2-[4-(4-Benzoyl-piperidin-1-yl)-butoxy]-5-methoxy-phenyl}-benzothiazol-3-yl)-propan-1-one 
• 112946-50-6 1-(2-{2-[4-(4-Benzoyl-piperidin-1-yl)-butoxy]-5-nitro-phenyl}-benzothiazol-3-yl)-ethanone 
• 139676-51-0 4-benzoyl-1-(2-hydroxyethyl)piperidine 
• 114399-88-1 α,α-diphenyl-1-(phenylmethyl)-4-piperidinemethanol 
• 202124-80-9 1-(4-Benzoylpiperidinecarbonyl)methyl-5-cyanoindole 
• 1027540-75-5 [2-(4-benzoyl-piperidin-1-yl)-2-oxo-1-phenyl-ethyl]-carbamic acid tert-butyl ester 
• 1050826-75-9 [1-(2-nitro-benzyl)-piperidin-4-yl]-phenyl-methanone 
• 92040-00-1 (1-methylpiperidin-4-yl)(phenyl)methanone 

Relevant articles and documents

Optimization of a Benzoylpiperidine Class Identifies a Highly Potent and Selective Reversible Monoacylglycerol Lipase (MAGL) Inhibitor

Monoacylglycerol lipase (MAGL) is the enzyme degrading the endocannabinoid 2-arachidonoylglycerol, and it is involved in several physiological and pathological processes. The therapeutic potential of MAGL is linked to several diseases, including cancer. The development of MAGL inhibitors has been greatly limited by the side effects associated with the prolonged MAGL inactivation. Importantly, it could be preferable to use reversible MAGL inhibitors in vivo, but nowadays only few reversible compounds have been developed. In the present study, structural optimization of a previously developed class of MAGL inhibitors led to the identification of compound 23, which proved to be a very potent reversible MAGL inhibitor (IC50 = 80 nM), selective for MAGL over the other main components of the endocannabinoid system, endowed of a promising antiproliferative activity in a series of cancer cell lines and able to block MAGL both in cell-based as well as in vivo assays.

PIPERIDINE UREA DERIVATIVES

Compounds of the formula I in which R1-R3 have the meanings indicated in Claim 1, are inhibitors of Tankyrase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation.

Synthesis and in vitro and in vivo evaluation of18F-labeled positron emission tomography (PET) ligands for imaging the vesicular acetylcholine transporter

A new class of vesicular acetylcholine transporter inhibitor that incorporates a carbonyl group into the benzovesamicol structure was synthesized, and analogues were evaluated in vitro. (±)-trans-2-Hydroxy-3- (4-(4-[18F]fluorobenzoyl)piperidino)tetralin (9e) has Ki values of 2.70 nM for VAChT, 191 nM for σ1 and 251 nM for σ2. The racemic precursor (9d) was resolved via chiral HPLC, and (±)-[18F]9e,(-)-[18F]9e, and (+)-[ 18F]9e were respectively radiolabeled via microwave irradiation of the appropriate precursors with [18F]/F- and Kryptofix/K 2CO3 in DMSO with radiochemical yields of ～50-60% and specific activities of >2000 mCi/μmol. (-)-[18F]9e uptake in rat brain was consistent with in vivo selectivity for the VAChT with an initial uptake of 0.911 %ID/g in rat striatum and a striatum/cerebellum ratio of 1.88 at 30 min postinjection (p.i.). MicroPET imaging of macaques demonstrated a 2.1 ratio of (-)-[18F]9e in putamen versus cerebellum at 2 h p.i. (-)-[18F]9e has potential to be a PET tracer for clinical imaging of the VAChT.